<DOC>
	<DOCNO>NCT02879630</DOCNO>
	<brief_summary>Patients receive acyclovir standard care enrol study . The currently recommend dose strategy institution obese patient receive intravenous acyclovir dose per adjust body weight [ IBW + 0.4 ( TBW-IBW ) ] . They blood drawn prior first dose acyclovir 10 time thereafter , total time period 12 hour . These patient already hospitalize reason , require make additional trip hospital . A total approximately 4-5 tablespoon blood drawn study . Ten obese patient 10 match control ( non-obese ) patient enrol .</brief_summary>
	<brief_title>Prospective Evaluation Adjusted Body Weight Dosing Acyclovir Obesity</brief_title>
	<detailed_description />
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Body Weight</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>Age â‰¥18 year age Receiving intravenous acyclovir 5 mg/kg ( TBW normal weight patient ABW40 obese patient ) part routine care Weight &gt; 190 % ideal body weight ( IBW ) `` obese '' patient weight 80120 % IBW match control patient . Receipt acyclovir prodrug acyclovir ( valacyclovir , ganciclovir , valganciclovir , famciclovir ) prior 24 hour Serum creatinine &gt; 1.5 mg/dL Hypersensitivity acyclovir Patients require ventilator support vasopressor prior 24 hour Receipt probenecid , mycophenolate , tenofovir , zidovudine prior 7 day Significant anatomical deformity influence body habitus ( i.e . amputation ) Prior inclusion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>pharmacokinetics</keyword>
	<keyword>acyclovir</keyword>
</DOC>